Multiple Myeloma Clinical Trial
Official title:
A Phase I/II Study of Oral Melphalan Combined With LBH589 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Verified date | April 2014 |
Source | Oncotherapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing.
Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Giving melphalan together with panobinostat may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of melphalan when
given together with panobinostat in treating patients with recurrent multiple myeloma.
Status | Completed |
Enrollment | 40 |
Est. completion date | December 2012 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Diagnosis of multiple myeloma, based on the following criteria: - Major criteria - Plasmacytomas on tissue biopsy (1) - Bone marrow plasmacytosis (> 30% plasma cells) (2) - Monoclonal immunoglobulin (Ig) spike on serum electrophoresis, IgG > 3.5 g/dL or IgA > 2.0 g/dL, and kappa or lambda light chain excretion > 1 g/day on 24-hour urine protein electrophoresis (3) - Minor Criteria - Bone marrow plasmacytosis (10-30% plasma cells) (a) - Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria (b) - Lytic bone lesions ©) - Normal IgM < 50 mg/dL, IgA < 100 mg/dL, or IgG < 600 mg/dL (d) - Meets any of the following sets of multiple myeloma diagnostic criteria: - Any two of the major criteria - Major criterion 1 plus minor criterion b, c, or d - Major criterion 3 plus minor criterion a or c - Minor criteria a, b, and c, OR a, b, and d - Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of = 1 g/dL and/or urine monoclonal immunoglobulin spike of = 200 mg/24 hours, or evidence of lytic bone disease - Must have received = 1 prior treatment regimen OR refractory to most recent chemotherapy - Relapsed following stabilization or response to standard first-line chemotherapy (e.g., vincristine, doxorubicin hydrochloride, and prednisone or melphalan and prednisone) or first-line high-dose chemotherapy - Refractory (i.e., failure to achieve at least complete or partial response or stable disease) to most recent chemotherapy, whether or not containing systemic corticosteroids - Prior treatment with = 4 days of a total of 400 mg of prednisone (or an equivalent potency of another steroid) for myeloma is not considered a regimen - Eastern Cooperative Oncology Group (ECOG) performance status = 2 - Life expectancy > 3 months - Platelet count = 75 x 10^9/L (= 50 x 10^9/L if bone marrow is extensively infiltrated) - Absolute neutrophil count = 1.5 x 10^9/L (= 1.0 x 10^9/L if bone marrow is extensively infiltrated) - Aspartate transaminase (AST) and Alanine transaminase (ALT) = 2.5 times upper limit of normal (ULN) - Serum bilirubin = 1.5 times ULN - Creatinine clearance = 30 mL/min; creatinine > 10 mL/min and < 30 mL/min due to significant myelomatous involvement of the kidneys allowed with medical director approval - Serum potassium = lower limit of normal (LLN) - Serum magnesium = LLN - Serum phosphorus = LLN - Prior localized radiotherapy Exclusion criteria: - Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS syndrome) - Plasma cell leukemia - Pregnant or nursing females; fertile patients must use effective contraception - Peripheral neuropathy > grade 2 - Impaired cardiac function or clinically significant cardiac disease (including congenital long QT syndrome, history or presence of sustained ventricular tachyarrhythmia; history of ventricular fibrillation or Torsade de Pointes; bradycardia, defined as heart rate (HR) < 50 beats per minute (bpm) [pacemaker allowed provided HR = 50 bpm]; corrected QT interval > 450 msec on screening ECG; left ventricular ejection fraction below normal on screening ECHO or multigated acquisition (MUGA) scan; right bundle branch block with left anterior hemiblock (bifascicular block); myocardial infarction or unstable angina within the past 6 months; New York Heart Association class III-IV congestive heart failure; uncontrolled hypertension; history of labile hypertension; history of poor compliance with an antihypertensive regimen) - Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat - Prior malignancy within the past 5 years except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix - Other concurrent severe and/or uncontrolled medical or psychiatric conditions (e.g., uncontrolled diabetes or active or uncontrolled infection), including abnormal laboratory values that could cause unacceptable safety risks or compromise protocol compliance - Known positivity for HIV or hepatitis B or C - Severe hypercalcemia (i.e., serum calcium = 14 mg/dL) - Significant history of non-compliance to medical regimens or unwillingness or inability to comply with instructions given by the study staff - Concurrent medication that risk prolonging the QT interval or inducing Torsades de Pointes - Prior panobinostat - Received chemotherapy, bortezomib, thalidomide, lenalidomide or arsenic trioxide within 3 wks of enrollment (with the exception of nitrosoureas within 6 wks of enrollment) - Received corticosteroids (>10 mg/day prednisone or equivalent) within three weeks before enrollment. - Received immunotherapy within < 8 weeks; antibody within < 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within < 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Comprehensive Blood and Cancer Center | Bakersfield | California |
United States | Center for Cancer and Blood Disorders | Bethesda | Maryland |
United States | Rocky Mountain Cancer Centers - Denver Midtown | Denver | Colorado |
United States | James R. Berenson MD, Incorporated | West Hollywood | California |
Lead Sponsor | Collaborator |
---|---|
Oncotherapeutics | Novartis |
United States,
Berenson JR, Hilger JD, Yellin O, Boccia RV, Matous J, Dressler K, Ghazal HH, Jamshed S, Kingsley EC, Harb WA, Noga SJ, Nassir Y, Swift RA, Vescio R. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory m — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Tolerated Dose (MTD) | Phase 1: to determine the MTD of panobinostat (LBH589) in combination with melphalan to be used in the Phase 2 portion of the study | 12 months | Yes |
Primary | MTD | Phase 1: to determine MTD of melphalan in combination with panobinostat to be used in the Phase 2 portion of the study | 12 months | Yes |
Primary | Overall Response Rate (ORR) and Clinical Benefit Rate (CBR) [ORR= Complete Response (CR) + Very Good Partial Response (VGPR) + Partial Response (PR)]; CBR=ORR + Minimal Response (MR)] Following Treatment With Panobinostat and Melphalan | Responses were evaluated according to criteria modified from those developed by Blade et al., 1998 The reference point for evaluating response improvement is the baseline. This baseline reference point is also valid when a patient has already achieved a response and transitions through into a better response grade. | 24 months | No |
Secondary | Duration of Response | First evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death | No | |
Secondary | Time to Progression | Time from the start of treatment to progressive disease | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |